Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simtuzumab in Liver Fibrosis
NCT01452308Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Nov 2011
- Primary completion
- Jan 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of simtuzumab in Liver Fibrosis (LF), sponsored by Gilead Sciences. Started Nov 2011; status: completed.
02
Drugs
simtuzumab
03
Conditions
Liver Fibrosis (LF)
Beyond the preview
Go deeper on NCT01452308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01452308.